Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for April 28, 2026 to review and approve its first quarterly report for the period ended March 31, 2026. The meeting may also cover additional board resolutions, signaling routine corporate governance activity that will update investors on the company’s early 2026 operating and financial performance.
The announcement confirms the current composition of Tigermed’s board, which includes executive and independent non-executive directors, underscoring adherence to Hong Kong listing requirements on oversight and independence. Stakeholders will look to the forthcoming quarterly report for insight into business momentum in the new financial year and any strategic signals from the board.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a clinical research and development service provider based in the People’s Republic of China. Listed in Hong Kong under stock code 3347, the company operates through its subsidiaries to support pharmaceutical and biotech clients with outsourced clinical trial and consulting services across the drug development value chain.
Average Trading Volume: 1,887,501
Technical Sentiment Signal: Hold
Current Market Cap: HK$51.2B
See more data about 3347 stock on TipRanks’ Stock Analysis page.